Experimental CAR t therapy for severe muscle weakness hits early hurdle

This early trial tested an experimental drug called HN2301, a type of CAR T cell therapy made inside the body, for people with refractory myasthenia gravis — a condition causing severe muscle weakness that doesn't respond well to standard treatments. The study planned to enroll 9 adults to check safety and how well the therapy works, but it was terminated early. Because it stopped early and included very few people, we don't have clear answers on whether this approach is safe or effective.